numerous flame haemorrhages and soft exudates. The heart was enlarged and a left ventricular diastolic gallop was heard. The rest of the physical examination including a complete neurological examination was within normal limits.
The urine analysis showed two-plus proteinuria and a normal sediment. The blood urea nitrogen was 75 mg./100 ml. and the serum creatinine 13.5 mg./100 ml. Tests for secondary forms of hypertension were negative and included a normal 24-hour excretion of urinary catecholamines.
The effect of her admission to hospital alone on the blood pressure is shown for days 1 to 3 in the Chart. Beginning on day 3, bethanidine sulphate 20 mg. by mouth daily was given in divided doses, satisfactory blood pressure control being obtained on days 4 to 11, with regression of the papilloedema. On the evening of day 11 the patient complained of a cold with mild rhinitis and was given one Spansule of Ornade. On day 12 the dosage of Ornade was repeated twice at an interval of 12 hours. The blood pressure rose soon after the first dose and remained at high levels until day 16. Papilloedema recurred and severe headache with mental confusion supervened late on day 15.
Intravenous diazoxidet (300 mg.) on days 15 and 16 produced a less-than-usual response, and trimetaphan camsylate intravenously (8 and 16 mg./min.) was without effect on the blood pressure. Intravenous phentolamine hydrochloride (5 mg.), however, repeatedly produced a dramatic depressor response, albeit a transitory one. The blood pressure was finally controlled only with methyldopa intravenously on day 17, followed by the oral form until discharge from hospital. COMMENT A list of various drugs known to antagonize the actions of adrenergic neuronal blocking agents is shown in the Table. To this list must be added phenylpropanolamine, a sympathomimetic drug which is one of the active ingredients of Ornade.
The postulated mechanisms whereby various compounds antagonize the actions of adrenergic neuronal blocking agents are: (1) by interference with the uptake of the neuronal blocking agent into the adrenergic neuron, where it must be concentrated to exert its effect; and (2) by preventing the physiological re-uptake of released noradrenaline back into the adrenergic neuron. The latter may result in increased amounts of noradrenaline accumulating locally about the adrenergic neuron and receptor4 and may be an explanation for the depressor response noted with phentolamine hydrochloride in our patient. 
